GlassScriptPhysician profile
Sharon A Goble
NPI 1255394417
$861.31
in general payments reported to CMS, 2019-2025
24 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.19 · 2021: $22.97 · 2022: $162 · 2023: $203 · 2024: $210 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $139.50 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $114.78 | 2022-2025 | |
| Janssen Biotech, INC. | $86.65 | 2019-2023 | Imbruvica, Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $55.68 | 2022-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $41.13 | 2023-2024 | Krazati |
| Array Biopharma INC | $35.88 | 2025 | Lorbrena, Braftovi |
| Genzyme Corporation | $33.92 | 2025 | |
| Merck Sharp & Dohme LLC | $33.73 | 2023-2024 | Keytruda |
| Pfizer INC. | $32.88 | 2023-2025 | |
| Gilead Sciences, INC. | $30.03 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2025 | Libtayo |
| Eisai INC. | $26.32 | 2024 | |
| Accord Healthcare, INC. | $25.72 | 2025 | |
| Karyopharm Therapeutics INC. | $24.57 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.14 | 2023 | Tagrisso |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.44 | 2024 | |
| Kite Pharma, INC. | $21.25 | 2022 | |
| Amgen INC. | $19.37 | 2023 | Lumakras |
| Springworks Therapeutics, INC. | $18.50 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $13.40 | 2024 | Sancuso |
| Incyte Corporation | $13.37 | 2023 | Jakafi, Pemazyre, Monjuvi |
| Seagen INC. | $12.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.05 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Goble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.